I-Flow welcomes AcryMed as 2007 growth exceeds forecasts
This article was originally published in Clinica
I-Flow, the Lake Forest, California-based manufacturer of pain management systems, said total sales for 2007 outpaced its expectations by increasing 24% to $116.5m. The company had previously forecast annual sales growth to be 20%. Sales of its regional anaesthesia products, which provide site-specific pain management, were also better than expected, growing 32% to $89.6m. In conjunction with its preliminary 2007 results, the firm announced the closing of its acquisition of AcryMed. I-Flow inked a $25m all-cash deal to buy the Beaverton, Oregon-based developer of silver-based infection control and wound healing technologies in December 2007 (see Clinica No 1287, p 12).
You may also be interested in...
In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.